What Did Bremelanotide Change in Low-Desire Trials?

Before a treatment appointment, separate what changed from what you want help with: desire, distress about desire, arousal or pain. They give the clinician different questions to investigate.

Who took part in RECONNECT?

24-week trials randomized 1,267 premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD); 1,202 entered efficacy analyses. They tested bremelanotide 1.75 mg injected under the skin as needed, versus placebo. Participants were mostly white, in monogamous relationships; antidepressant users were excluded.¹

The current US VYLEESI label covers premenopausal women with distressing acquired, generalized HSDD unexplained by medical or psychiatric illness, relationship problems or medicines. Acquired means developing after previously normal desire; generalized means across situations or partners. Low desire alone does not establish eligibility.²

Did desire improve, or did sexual events increase?

Both primary outcomes improved significantly. Pooled differences versus placebo were +0.35 on the 1.2–6 desire scale and −0.33 on the 0–4 bother scale. The key secondary count of satisfying sexual events did not significantly improve. A percentage-based analysis was exploratory.¹

Withdrawal was 41.9% versus 16.0% in one trial and 43.8% versus 28.4% in the other. Analyses carried forward earlier observations; results do not represent everyone completing 24 weeks. Palatin sponsored the studies; authors disclosed company ties.¹

Which safety issues need discussion?

Nausea affected 40.0% with bremelanotide versus 1.3% with placebo.¹

VYLEESI is contraindicated with uncontrolled hypertension or known cardiovascular disease. It transiently raises blood pressure; the label requires cardiovascular-risk and blood-pressure review before and during treatment.²

Discuss persistent nausea and skin darkening, which may persist. Avoid VYLEESI with oral naltrexone for addiction. The label limits dosing to once per 24 hours and advises against more than eight monthly doses. It advises effective contraception and stopping if pregnancy is suspected.²

How should benefit be reviewed?

The label says to stop after eight weeks without symptom improvement. Agree on the review plan with the prescriber. It is not indicated after menopause or for sexual-performance enhancement.²

The “Problem Versus Bothered” section of Down There, Decoded asks whether the change bothers you. Its Down-There Log records what changed, when it changed and what you’ve tried. Bring that account, including the timing of new medicines, rather than measuring success only by how often sex happens.